Moneycontrol
HomeNewsBusinessPfizer gets three-year reprieve from Trump pharma tariffs
Trending Topics

Pfizer gets three-year reprieve from Trump pharma tariffs

Pfizer will sell some drugs at a 50% average discount on a direct-to-consumer website called TrumpRx, an initiative intended to allow Americans to pay for prescriptions at discounted rates negotiated by the government.

September 30, 2025 / 22:50 IST
Story continues below Advertisement
Albert Bourla, chief executive officer of Pfizer Inc., during a Bloomberg Television interview in New York, US, on Tuesday, Oct. 31, 2023. Pfizer Inc.'s sales missed expectations for the quarter as its Covid-19 shot and pill continued to create instability for the drugmaker's efforts to transition out of the pandemic. Photographer: Jeenah Moon/Bloomberg

Pfizer Inc. Chief Executive Officer Albert Bourla said the company secured a three-year grace period from President Donald Trump’s promised tariffs on pharmaceuticals in a deal that would lower some of the company’s US drug prices.

Pfizer will sell some drugs at a 50% average discount on a direct-to-consumer website called TrumpRx, an initiative intended to allow Americans to pay for prescriptions at discounted rates negotiated by the government.

Story continues below Advertisement

The deal appears to resolve two major threats facing Pfizer. It would stave off more damaging drug pricing policies while shielding the company from future tariffs imposed by the administration’s Section 232 investigation into whether the cost of medicine represents a national security threat.

It’s the latest example of the transactional nature of winning tariff exemptions from Trump, who has unilaterally wielded trade policy to exert power over multiple industries. As recently as last week, Trump threatened 100% tariffs on the pharma industry.